Monday 6-17-2014 Achillion Pharmaceuticals (ACHN) $ACHN opened at 7.55 hitting the high price of 7.72 and a day low of 7.25 with a total volume of 13,367,118. ACHN had a previous close of 7.82 and has been seeing an average volume of 12,247,785.
Overall Average: 80% Buy
Recent stock forum discussions about ACHN http://investorshangout.com/search?q=ACHN&...mp;yt0=Go!
Nasdaq stocks posting largest volume increases
AP - Tue Jun 17, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading: (full story)
Nasdaq stocks posting largest percentage increases
AP - Tue Jun 17, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading: (full story)
Most active Nasdaq-traded stocks
AP - Tue Jun 17, 5:03PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading: (full story)
Critical Alerts For Bank of America, Achillion Pharmaceuticals, Walmart, SunEdison, and Advanced Micro Devices Released By InvestorsObserver
PR Newswire - Tue Jun 17, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BAC, ACHN, WMT, SUNE, and AMD. (full story)
Achillion Gets Massive Price Target Hike On HCV Drugs
at Investor's Business Daily - Mon Jun 16, 10:18PM CDT
Biotech Achillion Pharmaceuticals (ACHN) got another boost Monday when Maxim Group more than tripled its price target on the stock, sending shares up 21% on the stock market today. After having dinner with company executives, analyst Jason Kolbert... (full story)
Achillion gets price target hike
at Investor's Business Daily - Mon Jun 16, 5:56PM CDT
The biotech company's shares soared 20.9% to 7.82 after Maxim Group more than tripled its price target on Achillion Pharmaceuticals (ACHN) stock. Analyst Jason Kolbert increased his target to 22 from 6 on the potential of hepatitis C drug candidates,... (full story)
Why Fusion-io, Achillion Pharmaceuticals, and Covidien Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Mon Jun 16, 4:15PM CDT
Following the first down week for the broad-based S&P 500 in quite some time investors were looking for something positive to start their work week, and a bevy of economic data gave them what they were looking for. Industrial production... (full story)
Why Achillion Pharmaceuticals (ACHN) Is Spiking Today
at The Street - Mon Jun 16, 9:33AM CDT
Achillion Pharmaceuticals (ACHN) is rocketing up after having its price target raised significantly to $22 from $6 by analysts at Maxim. (full story)
3 Stocks That Soared Stupendously This Week
Keith Speights, The Motley Fool - Motley Fool - Sun Jun 15, 8:15AM CDT
How would you like a 40% gain in one week? How about gains of over 120% -- or more than 220%? Shareholders of three health-care stocks don't have to wonder how they'd like those types of returns. They experienced the joy first-hand. One of this... (full story)
This Week in Biotech: Actions Speak Louder Than Words
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 14, 10:20AM CDT
With the SPDR S&P Biotech Index up 39% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and... (full story)
Today's Top Biotech Stocks to Watch: Achillion Pharmaceuticals, Nektar Therapeutics and Progenics Ph
George Budwell, The Motley Fool - Motley Fool - Fri Jun 13, 8:02AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Achillion Pharmaceuticals , Nektar Therapeutics and Progenics Pharmaceuticals . Achillion falling back down to Earth Shares of hepatitis C... (full story)
If Achillion Pharmaceuticals (NASDAQ: ACHN) Investors Are Hoping for a Buyout, This is Not an Investment Strategy; Analyst Report by BrokerBank Securities, Inc.
PR Newswire - Fri Jun 13, 6:00AM CDT
Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) is a biopharmaceutical company that is engaged in the discovery, development and commercialization of innovative treatments for infectious diseases. Within the anti-infective market, the company is primarily focused on developing commercially competitive, short duration combination therapies for the treatment of chronic hepatitis C virus (HCV) that are once-daily and ribavirin-free. (full story)
Overall Average: 80% Buy
Recent stock forum discussions about ACHN http://investorshangout.com/search?q=ACHN&...mp;yt0=Go!
Nasdaq stocks posting largest volume increases
AP - Tue Jun 17, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading: (full story)
Nasdaq stocks posting largest percentage increases
AP - Tue Jun 17, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading: (full story)
Most active Nasdaq-traded stocks
AP - Tue Jun 17, 5:03PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading: (full story)
Critical Alerts For Bank of America, Achillion Pharmaceuticals, Walmart, SunEdison, and Advanced Micro Devices Released By InvestorsObserver
PR Newswire - Tue Jun 17, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for BAC, ACHN, WMT, SUNE, and AMD. (full story)
Achillion Gets Massive Price Target Hike On HCV Drugs
at Investor's Business Daily - Mon Jun 16, 10:18PM CDT
Biotech Achillion Pharmaceuticals (ACHN) got another boost Monday when Maxim Group more than tripled its price target on the stock, sending shares up 21% on the stock market today. After having dinner with company executives, analyst Jason Kolbert... (full story)
Achillion gets price target hike
at Investor's Business Daily - Mon Jun 16, 5:56PM CDT
The biotech company's shares soared 20.9% to 7.82 after Maxim Group more than tripled its price target on Achillion Pharmaceuticals (ACHN) stock. Analyst Jason Kolbert increased his target to 22 from 6 on the potential of hepatitis C drug candidates,... (full story)
Why Fusion-io, Achillion Pharmaceuticals, and Covidien Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Mon Jun 16, 4:15PM CDT
Following the first down week for the broad-based S&P 500 in quite some time investors were looking for something positive to start their work week, and a bevy of economic data gave them what they were looking for. Industrial production... (full story)
Why Achillion Pharmaceuticals (ACHN) Is Spiking Today
at The Street - Mon Jun 16, 9:33AM CDT
Achillion Pharmaceuticals (ACHN) is rocketing up after having its price target raised significantly to $22 from $6 by analysts at Maxim. (full story)
3 Stocks That Soared Stupendously This Week
Keith Speights, The Motley Fool - Motley Fool - Sun Jun 15, 8:15AM CDT
How would you like a 40% gain in one week? How about gains of over 120% -- or more than 220%? Shareholders of three health-care stocks don't have to wonder how they'd like those types of returns. They experienced the joy first-hand. One of this... (full story)
This Week in Biotech: Actions Speak Louder Than Words
Sean Williams, The Motley Fool - Motley Fool - Sat Jun 14, 10:20AM CDT
With the SPDR S&P Biotech Index up 39% over the trailing 12-month period , it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and... (full story)
Today's Top Biotech Stocks to Watch: Achillion Pharmaceuticals, Nektar Therapeutics and Progenics Ph
George Budwell, The Motley Fool - Motley Fool - Fri Jun 13, 8:02AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Achillion Pharmaceuticals , Nektar Therapeutics and Progenics Pharmaceuticals . Achillion falling back down to Earth Shares of hepatitis C... (full story)
If Achillion Pharmaceuticals (NASDAQ: ACHN) Investors Are Hoping for a Buyout, This is Not an Investment Strategy; Analyst Report by BrokerBank Securities, Inc.
PR Newswire - Fri Jun 13, 6:00AM CDT
Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) is a biopharmaceutical company that is engaged in the discovery, development and commercialization of innovative treatments for infectious diseases. Within the anti-infective market, the company is primarily focused on developing commercially competitive, short duration combination therapies for the treatment of chronic hepatitis C virus (HCV) that are once-daily and ribavirin-free. (full story)
